Literature DB >> 28067540

Soluble ST2 is associated with disease severity in arrhythmogenic right ventricular cardiomyopathy.

Kaspar Broch1,2, Ida S Leren1,3, Jørg Saberniak1,3, Thor Ueland4,5, Thor Edvardsen1,3,5, Lars Gullestad1,2,5, Kristina H Haugaa1,3,5.   

Abstract

PURPOSE: Diagnostic and prognostic evaluation remains challenging in arrhythmogenic right ventricular cardiomyopathy (ARVC). We measured plasma concentration of soluble ST2 (sST2) and assessed its association with right ventricular (RV) function and ventricular arrhythmias in patients with ARVC.
METHODS: We included patients with ARVC and genotype positive relatives. Soluble ST2 was determined by ELISA. We assessed myocardial function by echocardiography including strain by speckle tracking technique.
RESULTS: We included 44 subjects (age 41 ± 15 years, 21 (48%) female). Soluble ST2 was associated with RV global strain (r = 0.44; p = 0.008), as well as with left ventricular (LV) function. Plasma levels of sST2 were higher in patients with ventricular arrhythmias than in patients without ventricular arrhythmias (35 ± 13 ng/mL vs. 26 ± 7 ng/mL, p = 0.009). The association between sST2 and ventricular arrhythmias remained significant even after adjusting for RV function (Wald = 5.2; p = 0.02).
CONCLUSIONS: Soluble ST2 is associated with RV and LV function in patients with ARVC. Soluble ST2 may aid in the determination of disease severity in ARVC.

Entities:  

Keywords:  Arrhythmogenic right ventricular cardiomyopathy; ST2; biomarker; right ventricular function; ventricular arrhythmia

Mesh:

Substances:

Year:  2017        PMID: 28067540     DOI: 10.1080/1354750X.2016.1278266

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  6 in total

Review 1.  Definition and treatment of arrhythmogenic cardiomyopathy: an updated expert panel report.

Authors:  Perry M Elliott; Aris Anastasakis; Angeliki Asimaki; Cristina Basso; Barbara Bauce; Matthew A Brooke; Hugh Calkins; Domenico Corrado; Firat Duru; Kathleen J Green; Daniel P Judge; David Kelsell; Pier D Lambiase; William J McKenna; Kalliopi Pilichou; Alexandros Protonotarios; Jeffrey E Saffitz; Petros Syrris; Hari Tandri; Anneline Te Riele; Gaetano Thiene; Adalena Tsatsopoulou; J Peter van Tintelen
Journal:  Eur J Heart Fail       Date:  2019-06-18       Impact factor: 15.534

2.  Increased levels of sST2 in patients with mitral annulus disjunction and ventricular arrhythmias.

Authors:  Esther Scheirlynck; Lars A Dejgaard; Eystein Skjølsvik; Oyvind H Lie; Andreea Motoc; Einar Hopp; Kaoru Tanaka; T Ueland; Margareth Ribe; Carlos Collet; Thor Edvardsen; Steven Droogmans; Bernard Cosyns; Kristina H Haugaa
Journal:  Open Heart       Date:  2019-04-28

Review 3.  Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) in clinical practice.

Authors:  Ka Hou Christien Li; George Bazoukis; Tong Liu; Guangping Li; William K K Wu; Sunny Hei Wong; Wing Tak Wong; Yat Sun Chan; Martin C S Wong; Katharina Wassilew; Vassilios S Vassiliou; Gary Tse
Journal:  J Arrhythm       Date:  2017-12-21

4.  ST2 levels increased and were associated with changes in left ventricular systolic function during a three-year follow-up after adjuvant radiotherapy for breast cancer.

Authors:  Hanna Aula; Tanja Skyttä; Suvi Tuohinen; Tiina Luukkaala; Mari Hämäläinen; Vesa Virtanen; Pekka Raatikainen; Eeva Moilanen; Pirkko-Liisa Kellokumpu-Lehtinen
Journal:  Breast       Date:  2019-12-06       Impact factor: 4.380

5.  Using Soluble ST2 to Predict Adverse Postoperative Outcomes in Patients with Impaired Left Ventricular Function Undergoing Coronary Bypass Surgery.

Authors:  Ahmet Dolapoglu; Eyup Avci; Tarik Yildirim; Hasan Kadi; Ahmet Celik
Journal:  Medicina (Kaunas)       Date:  2019-09-07       Impact factor: 2.430

6.  Metabolic Signature of Arrhythmogenic Cardiomyopathy.

Authors:  Chiara Volani; Johannes Rainer; Vinicius Veri Hernandes; Viviana Meraviglia; Peter Paul Pramstaller; Sigurður Vidir Smárason; Giulio Pompilio; Michela Casella; Elena Sommariva; Giuseppe Paglia; Alessandra Rossini
Journal:  Metabolites       Date:  2021-03-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.